stock-detail (BMY)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

At Cancer Moonshot Summit, Vice President Biden Announces New Actions to Accelerate Progress Toward Ending Cancer As We Know It

6/29/2016 12:03 pm

(WhiteHouse.gov) June 28, 2016 - Today, the Cancer Moonshot is hosting a summit at Howard University, in Washington, D.C. as part of a national day of action that also includes more than 270 events in communities across the United States.

How Telemedicine Is Changing Health Care

6/27/2016 12:00 pm

(Wall Street Journal) June 26, 2016 - The revolution is finally here—raising a host of questions for regulators, providers, insurers and patients.

In Letter to Franken, FDA Defends Handling Of Medtronic's Infuse Study

6/23/2016 11:04 am

(Minneapolis Star Tribune) June 22, 2016 - The U.S. Food and Drug Administration is defending a decision to accept more than 1,000 patient injury reports from Medtronic in summary form, years after they were supposed to be submitted.

ESMO 2016: From Disease Treatment to Patient Care

6/14/2016 12:00 pm

(ESMO) June 13, 2016 - Nearly 2,900 abstracts were submitted for inclusion within the ESMO 2016 Congress, marking a 70% increase over the past six years and confirming the ESMO Congress as the leading oncology event in Europe.

Molecular Imaging of Neuroendocrine Tumors Optimizes Radiotherapy Dose

6/14/2016 11:05 am

(SNMMI) June 13, 2016 — Study shows the use of PET and SPECT tailors radionuclide treatment for neuroendocrine cancer patients and reduces the risk of toxicity.

New York Poised to Expand Access to Breast Cancer Screening

6/13/2016 12:01 pm

(ABC News/Associated Press) June 13, 2016 - New York is poised to expand access to breast cancer screening under an agreement reached by top state lawmakers and Democratic Gov. Andrew Cuomo, who made combating the cancer a priority after the successful cancer treatment of his girlfriend, Food Network star Sandra Lee.

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial

6/13/2016 12:00 pm

(NASDAQ) June 13, 2016 - ARIAD Pharmaceuticals, Inc. today announced long-term follow-up data from its pivotal Phase 2 PACE clinical trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Basilea Reports Presentation Of Data On Clinical Oncology Programs BAL101553 and BAL3833 at ASCO Meeting

6/9/2016 11:01 am

(Basilea Pharmaceutica) June 9, 2016 - Basilea Pharmaceutica Ltd. announced today that the final clinical data from the first-in-human phase 1/2a study with the intravenous (i.v.) form of its tumor checkpoint controller BAL101553 were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, USA, on June 3-7, 2016.

The US Oncology Network Holds Intensive Boot Camp to Prepare Oncology Practices for July Launch of Oncology Care Model (OCM)

6/8/2016 11:04 am

(McKesson) June 8, 2016 - Training program provides OCM tools, technology and experience, preparing practice teams for July 1st go-live.

ASCO: Extended PFS Seen With Early Myeloma Tx

6/7/2016 02:01 pm

(MedPage Today) June 7, 2016 - Multiple myeloma patients who have relapsed appear to achieve extended progression-free survival if they are treated with a carfilzomib-based 3-drug combination therapy after their first post-relapse line of treatment, researchers suggested here.

Biden, Cancer Groups Call for Collaboration to Hasten Advances

6/7/2016 02:00 pm

(Bloomberg) June 6, 2016 - Vice President Joe Biden called on cancer researchers and health organizations to set aside individual goals in treatment and research to work together on fighting the second-leading cause of death in the U.S.

AstraZeneca and Foundation Medicine Enter Strategic Collaboration for Lynparza Companion Diagnostic Assay

6/5/2016 06:03 pm

(AstraZeneca) June 4, 2016 - Foundation Medicine, Inc. and AstraZeneca today announced that they have entered into a definitive agreement to develop a novel companion diagnostic assay for Lynparza (olaparib) to support its global development program.

MD Anderson Study Identifies Significant Cost Differences Between Breast Cancer Chemotherapy Regimens

6/5/2016 06:03 pm

(MD Anderson) June 4, 2016 - Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research.

Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting

6/5/2016 06:01 pm

(Yahoo! Finance) June 5, 2016 - Exelixis, Inc. today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of cobimetinib, an Exelixis-discovered MEK inhibitor, in combination with atezolizumab, an anti-PD-L1 antibody discovered and developed by Genentech, in patients with metastatic colorectal cancer (CRC).

Long-Term Survival and Improvement in Quality of Life Observed with Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma Patients Based on New Data Presented at the 2016 ASCO Annual Meeting

6/5/2016 06:01 pm

(BMS) June 5, 2016 - Bristol-Myers Squibb Company announced today new long-term overall survival (OS) results from two dose-ranging studies, the Phase 1 CA209-003 study and the Phase 2 CA209-010 study, evaluating Opdivo in patients with previously treated advanced renal cell carcinoma (RCC).

Elderly Patients With Glioblastoma Live Longer With Chemoradiation Using Temozolomide

6/5/2016 06:00 pm

(2016 ASCO Annual Meeting) June 5, 2016 – A Canadian-led randomized phase III trial found that adding temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide, significantly improved survival of elderly patients with glioblastoma, reducing the risk of death by 33%.

Double Stem-Cell Transplant Improves Outcomes for Children with High-Risk Neuroblastoma

6/5/2016 06:00 pm

(2016 ASCO Annual Meeting) June 5, 2016 – A National Cancer Institute (NCI) funded phase III trial performed by the Children's Oncology Group found that adding a second autologous stem-cell transplant (ASCT, a transplant that uses the patient's own stem cells) to standard therapy improves outcomes for patients.

Escend Pharmaceuticals, Inc. Receives Orphan Drug Designation from the US Food and Drug Administration (FDA) for ES-3000 its Lead Compound in the Treatment of Chronic Myeloid Leukemia (CML)

6/4/2016 05:05 pm

(The Business Journals) June 2, 2016 - Escend Pharmaceuticals, Inc. announced today that its lead compound, ES-3000, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of chronic myeloid leukemia (CML).

Lexicon Announces The Launch Of Aboutcarcinoid.com To Provide Carcinoid Syndrome Disease Education To Patients, Caregivers And Physicians

6/4/2016 05:05 pm

(StreetInsider) June 2, 2016 - Lexicon Pharmaceuticals, Inc. today announced the launch of www.aboutcarcinoid.com to provide carcinoid syndrome disease education to patients, caregivers and physicians.

AbbVie Lays Out Long-Term Vision in Biotech Firm’s First R&D Day

6/4/2016 05:05 pm

(Bloomberg) June 3, 2016 - AbbVie has doubled down on cancer, buying Pharmacyclics Inc. last year for its blood cancer drug Imbruvica and, more recently, Stemcentrx Inc. for its experimental drugs targeting solid tumors.

Cancer Cell Therapies Could Be Approved Next Year: Juno, Kite Pharma

6/4/2016 05:04 pm

(Reuters) June 4, 2016 - A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells could begin reaching patients next year, according to companies presenting new data at the annual meeting of the American Society of Clinical Oncology.

Amgen Announces Launch Of KYPROLIS® (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers

6/4/2016 05:04 pm

(NASDAQ) June 3, 2016 - Amgen today announced the launch of KYPROLIS CENTRAL, an online media resource about the impact of living with relapsed or refractory multiple myeloma.

Kangmei Healthcare Cloud Service Co to Launch Cancer Therapy Management Services

6/4/2016 05:04 pm

(Yahoo! Finance) June 3, 2016 - Cloud EHR-based bi-lingual service platform for chinese-speaking cancer patients announced at 2016 ASCO Annual Meeting.

Roche Sues India’s Drug Regulator Over Avastin ‘Similar Biologics’

6/4/2016 05:04 pm

(GaBI) June 3, 2016 - Switzerland-based drug giant Roche has sued the Drug Controller General of India (DCGI) in the Delhi High Court over ‘similar biologic’ versions of its cancer blockbuster Avastin (bevacizumab).

Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20

6/4/2016 05:02 pm

(4-traders) June 4, 2016 - Halozyme Therapeutics, Inc. today announced results from a final analysis of 135 metastatic pancreatic cancer patients who were treated in Stage One of HALO 109-202, a phase 2 clinical study of its investigational new drug PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine (PAG arm) as compared to ABRAXANE and gemcitabine alone (AG arm).